Literature DB >> 35685252

Successful withdrawal of catecholamine with ivabradine administration in catecholamine-dependent heart failure.

Kohei Azuma1, Masanori Asakura1, Koichi Nishimura1, Saki Tahara1, Yuki Matsumoto1, Eri Manabe1, Kyung-Duk Min1, Masaharu Ishihara1.   

Abstract

Ivabradine is a heart rate (HR)-lowering agent that blocks hyperpolarization-activated cyclic nucleotide-gated channel in the sinus node without a negative inotropic effect on cardiac function. Here we report a case of catecholamine-dependent heart failure, who was intolerant to β blockers, and successfully withdrew catecholamine by administering ivabradine. A 39-year-old male acute decompensated heart failure (ADHF) patient with severe systolic cardiac failure, refractory to diuretic and dobutamine treatment was transferred to our hospital. In addition to titration of dobutamine support, intra-aortic balloon pump, mechanical ventilation, and continuous hemodiafiltration therapy were initiated. These mechanical supports could stabilize ADHF and were removed. Upon stabilization of ADHF, we attempted to initiate a low dose of bisoprolol and taper dobutamine, but the patient could not tolerate even a low dose of bisoprolol nor tapering of dobutamine. Since his HR was consistently above 100 beats per minute and ivabradine was reported to improve stroke volume (SV), we initiated ivabradine, and his SV remarkably increased after initiation. Consequently, the dose of dobutamine was successfully tapered. Also, additional clinical advantage of ivabradine, assessed through hemodynamic parameters, appeared to be a reduction in afterload. <Learning objective: Ivabradine is a heart rate (HR)-lowering agent that blocks the hyperpolarization-activated cyclic nucleotide-gated channel in the sinus node without a negative inotropic effect. In this present catecholamine-dependent advanced heart failure case, the patient could not tolerate even a low dose of bisoprolol nor tapering of dobutamine. Being intolerant to beta-blockers, we initiated the administration of ivabradine. And the initiation of ivabradine resulted in not only the reduction of HR, but also the improvement in stroke volume resulting in the reduction of afterload.>.
© 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Beta blockers; Dobutamine; Heart failure with reduced ejection fraction; Ivabradine; Severe systolic heart failure

Year:  2022        PMID: 35685252      PMCID: PMC9168998          DOI: 10.1016/j.jccase.2022.01.005

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  10 in total

1.  Effect of dietary stearic acid on plasma cholesterol and lipoprotein levels.

Authors:  A Bonanome; S M Grundy
Journal:  N Engl J Med       Date:  1988-05-12       Impact factor: 91.245

2.  New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility.

Authors:  Biykem Bozkurt; Mariana Bolos; Anita Deswal; Sameer Ather; Wenyaw Chan; Douglas L Mann; Blase Carabello
Journal:  J Card Fail       Date:  2011-12-22       Impact factor: 5.712

3.  Effects of ivabradine on endothelial function, aortic properties and ventricular-arterial coupling in chronic systolic heart failure patients.

Authors:  Ivano Bonadei; Edoardo Sciatti; Enrico Vizzardi; Davide Fabbricatore; Mattia Pagnoni; Laura Rossi; Valentina Carubelli; Carlo M Lombardi; Marco Metra
Journal:  Cardiovasc Ther       Date:  2018-03-06       Impact factor: 3.023

4.  Effective arterial elastance as index of arterial vascular load in humans.

Authors:  R P Kelly; C T Ting; T M Yang; C P Liu; W L Maughan; M S Chang; D A Kass
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

5.  Ivabradine on aortic stiffness in patients with heart failure.

Authors:  Gokay Nar; Sinan Inci; Gokhan Aksan; Selami Demirelli; Korhan Soylu; Serkan Yuksel; Okan Gulel; Atilla Icli
Journal:  J Investig Med       Date:  2015-04       Impact factor: 2.895

6.  Two cases of dilated cardiomyopathy with blood pressure-limited tolerability of cardioprotective agents improved by ivabradine.

Authors:  Takahiro Okumura; Hiroaki Hiraiwa; Takashi Araki; Takashi Mizutani; Yuki Kimura; Shingo Kazama; Naoki Shibata; Hideo Oishi; Tasuku Kuwayama; Toru Kondo; Ryota Morimoto; Toyoaki Murohara
Journal:  J Cardiol Cases       Date:  2020-11-23

7.  Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.

Authors:  Jan-Christian Reil; Jean-Claude Tardif; Ian Ford; Suzanne M Lloyd; Eileen O'Meara; Michel Komajda; Jeffrey S Borer; Luigi Tavazzi; Karl Swedberg; Michael Böhm
Journal:  J Am Coll Cardiol       Date:  2013-08-07       Impact factor: 24.094

8.  Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry.

Authors:  Shi-Jun Li; Ulrik Sartipy; Lars H Lund; Ulf Dahlström; Martin Adiels; Max Petzold; Michael Fu
Journal:  Circ Heart Fail       Date:  2015-08-04       Impact factor: 8.790

9.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

10.  Initiation of ivabradine in cardiogenic shock.

Authors:  Michael H Chiu; Jonathan G Howlett; Nakul C Sharma
Journal:  ESC Heart Fail       Date:  2019-07-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.